Indomethacin Suppositories for Post-ERCP Pancreatitis Prevention

Mechanism of Action and Efficacy

Rectal indomethacin (100 mg) administered immediately before or after ERCP significantly reduces the risk of post-ERCP pancreatitis through its anti-inflammatory effects, and the rectal route is preferred because it provides rapid systemic absorption while avoiding first-pass metabolism and ensuring efficacy in patients who cannot take oral medications during the procedure 1, 2
Multiple meta-analyses have consistently demonstrated that rectal NSAIDs significantly reduce both the incidence and severity of post-ERCP pancreatitis 1, 2
The European Society of Gastrointestinal Endoscopy (ESGE) strongly recommends routine rectal administration of 100 mg of indomethacin or diclofenac immediately before or after ERCP in all patients without contraindications 1

The rectal route provides several key advantages over oral administration, including bypassing first-pass hepatic metabolism, resulting in higher bioavailability, and allowing administration to patients who are fasting before the procedure or who may develop nausea/vomiting afterward 1, 3
The recommended dose is 100 mg administered rectally immediately before or after ERCP 1, 2
Timing is critical - the suppository should be given either just before the procedure begins or immediately after it concludes 3
The drug should be administered to all patients without contraindications to NSAIDs, regardless of their baseline risk for post-ERCP pancreatitis 1, 3

Contraindications include NSAID allergy, significant renal impairment, active peptic ulcer disease, and bleeding disorders 1, 3
For high-risk patients, consider combining rectal indomethacin with prophylactic pancreatic stent placement 1
Failure to administer the suppository at the optimal time (immediately before or after ERCP) may reduce its effectiveness 1
Forgetting to screen for contraindications to NSAIDs before administration 3